DelveInsight’s ‘Chemotherapy-induced Diarrhea Pipeline Insights‘ report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.
The Chemotherapy-induced Diarrhea Pipeline report provides a comprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.
Some of the key takeaways from the Chemotherapy-induced Diarrhea Pipeline report:
- The Chemotherapy-induced Diarrhea Pipeline report offers a rich analysis of 5+ key players and 5+ key therapies.
- Chemotherapy-induced Diarrhea pipeline comprises emerging therapies in different stages of the clinical phase such as FW-420, Mytesi, OQL051, DP 1038 and others.
- Some of the key companies working to strengthen the Chemotherapy-induced Diarrhea Pipeline are AzuRx BioPharma, Napo Pharmaceuticals, OnQuality Pharmaceuticals, Dauntless Pharmaceuticals, among others.
Request for Sample report to discover more about the therapies set to grab maximum patient pool @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights
Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.
Chemotherapy-induced Diarrhea Pipeline Drugs Immunostimulants
|
Drug |
Company |
Phase |
MoA |
RoA |
|
FW-420 |
AzuRx BioPharma |
Unknown |
MTOR protein inhibitors |
Oral/rectal |
|
Mytesi |
Napo Pharmaceuticals |
Phase III |
Chloride channel antagonists |
Oral |
|
OQL051 |
OnQuality Pharmaceuticals |
Discovery |
NA |
NA |
|
DP 1038 |
Dauntless Pharmaceuticals |
Phase II |
Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists |
Intranasal |
Chemotherapy-induced Diarrhea Therapeutic Assessment
The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
Scope of the Report Coverage: Global Key Players: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others. Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others.
Reach out @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights
Table of Contents
|
1 |
Report Introduction |
|
2 |
Chemotherapy-induced Diarrhea Disease Overview |
|
3 |
Chemotherapy-induced Diarrhea Pipeline Outlook |
|
4 |
Comparative Analysis |
|
5 |
Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage |
|
6 |
Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage |
|
7 |
Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis |
|
8 |
Inactive Chemotherapy-induced Diarrhea Pipeline Products |
|
9 |
Appendix |
|
10 |
Report Methodology |
|
11 |
Consulting Services |
|
12 |
Disclaimer |
|
13 |
About DelveInsight |
Visit to know more of what’s covered @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-diarrhea-pipeline-insights